1/ A pill that could transform HIV prevention - and pharma company @Merck is already rationing who gets it.
We've joined the global response demanding compulsory licences for generic alimatravir in every excluded country.
healthgap.org/press/activi...
We've joined the global response demanding compulsory licences for generic alimatravir in every excluded country.
healthgap.org/press/activi...
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir If Alimatravir is Approved, Merck’s Unethical Exclusion of Middle Inc...
healthgap.org
July 28, 2026 at 4:22 PM
1/ A pill that could transform HIV prevention - and pharma company @Merck is already rationing who gets it.
We've joined the global response demanding compulsory licences for generic alimatravir in every excluded country.
healthgap.org/press/activi...
We've joined the global response demanding compulsory licences for generic alimatravir in every excluded country.
healthgap.org/press/activi...
September 16, 2026 at 12:24 PM
Statement from #HealthGAP @asia-ilse.bsky.social @hji-sa.bsky.social @justtreatment.org Associação Brasileira Interdisciplinar de AIDS (the Brazilian Interdisciplinary AIDS Association, ABIA), Sankalp Rehabilitation Trust
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir If Alimatravir is Approved, Merck’s Unethical Exclusion of Middle Inc...
healthgap.org
July 24, 2026 at 12:40 PM
Statement from #HealthGAP @asia-ilse.bsky.social @hji-sa.bsky.social @justtreatment.org Associação Brasileira Interdisciplinar de AIDS (the Brazilian Interdisciplinary AIDS Association, ABIA), Sankalp Rehabilitation Trust
NGOs haben beim Europäischen Patentamt Einspruch gegen Mercks Patentanmeldung für Prodrug-Formen von Alimatravir, einem in der Entwicklung befindlichen Präparat zur monatlichen oralen HIV-PrEP, eingereicht. t1p.de/fxrfn
We call on the European Patent Office to reject Merck’s patent application relating to alimatravir
Salud por Derecho, together with four other organisations, has submitted third-party observations to the European Patent Office, calling for a patent application filed by Merck Sharp & Dohme (MSD) rel...
t1p.de
October 2, 2026 at 8:12 AM
NGOs haben beim Europäischen Patentamt Einspruch gegen Mercks Patentanmeldung für Prodrug-Formen von Alimatravir, einem in der Entwicklung befindlichen Präparat zur monatlichen oralen HIV-PrEP, eingereicht. t1p.de/fxrfn
🔊 We welcome Unitaid’s support for African licensees to manufacture alimatravir, a promising oral HIV prevention pill.
@unitaid.bsky.social
Read our joint statement with @unitaidcommunities.bsky.social here:
unitaidngodelegation.org/2026/08/03/s...
@unitaid.bsky.social
Read our joint statement with @unitaidcommunities.bsky.social here:
unitaidngodelegation.org/2026/08/03/s...
Statement on the Merck Voluntary License on Alimatravir and Unitaid’s Announced Support For African Licensees | UNITAID
unitaidngodelegation.org
August 4, 2026 at 9:58 AM
🔊 We welcome Unitaid’s support for African licensees to manufacture alimatravir, a promising oral HIV prevention pill.
@unitaid.bsky.social
Read our joint statement with @unitaidcommunities.bsky.social here:
unitaidngodelegation.org/2026/08/03/s...
@unitaid.bsky.social
Read our joint statement with @unitaidcommunities.bsky.social here:
unitaidngodelegation.org/2026/08/03/s...
Die Organisationen kritisieren die Patentanmeldung auf Prodrug-Derivate von Alimatravir als „Evergreening“ – eine Strategie, Patentschutz durch neue Patente auf geringfügig veränderte Varianten künstlich zu verlängern – und warnen, dass günstige Generika dadurch jahrelang blockiert werden könnten.
October 2, 2026 at 8:14 AM
Die Organisationen kritisieren die Patentanmeldung auf Prodrug-Derivate von Alimatravir als „Evergreening“ – eine Strategie, Patentschutz durch neue Patente auf geringfügig veränderte Varianten künstlich zu verlängern – und warnen, dass günstige Generika dadurch jahrelang blockiert werden könnten.
"If #Alimatravir is Approved, Merck’s Unethical Exclusion of Middle Income Countries will Prolong the Pandemic
Countries Must Issue Compulsory Licenses for Generic Alimatravir Now."
healthgap.org/press/activi...
Countries Must Issue Compulsory Licenses for Generic Alimatravir Now."
healthgap.org/press/activi...
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir If Alimatravir is Approved, Merck’s Unethical Exclusion of Middle Inc...
healthgap.org
July 25, 2026 at 6:52 PM
"If #Alimatravir is Approved, Merck’s Unethical Exclusion of Middle Income Countries will Prolong the Pandemic
Countries Must Issue Compulsory Licenses for Generic Alimatravir Now."
healthgap.org/press/activi...
Countries Must Issue Compulsory Licenses for Generic Alimatravir Now."
healthgap.org/press/activi...
“The timing of the announcement is notable because Merck is striking these deals while its medicine, known as alimatravir, is currently undergoing a pair of late-stage clinical trials. By doing so now, the company believes it will help the generic makers plan for wide-scale production”
Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
Merck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production started quickly.
www.statnews.com
July 24, 2026 at 10:52 AM
“The timing of the announcement is notable because Merck is striking these deals while its medicine, known as alimatravir, is currently undergoing a pair of late-stage clinical trials. By doing so now, the company believes it will help the generic makers plan for wide-scale production”
🧵 "...alimatravir for $3 a yr could be the cheapest #HIVprevention drug the world has ever seen... But it needs to be $3 everywhere, not just some places." - Sam Cross in the #AIDS2026 Economics of Impact session.
July 28, 2026 at 7:02 PM
🧵 "...alimatravir for $3 a yr could be the cheapest #HIVprevention drug the world has ever seen... But it needs to be $3 everywhere, not just some places." - Sam Cross in the #AIDS2026 Economics of Impact session.
🧵1️⃣ Das Pharmaunternehmen Merck (MSD) hat freiwillige Lizenzen des neuen (derzeit noch in Phase-3-Studien untersuchten und nicht zugelassenen) #HIV- Wirkstoffs Alimatravir ( #MK8527) für die medikamentöse HIV-Prophylaxe #PrEP angekündigt. Die Tablette muss nur einmal im Monat eingenommen werden.
/2
/2
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development - Merck.com
Multi-faceted strategy aims to enable rapid, broad and sustainable access to alimatravir (MK-8527), if approved, in low- and middle-income countries Voluntary licensing agreements cover 129 countries ...
www.merck.com
July 24, 2026 at 3:36 PM
Africa shouldn’t have to wait years for the next generation of HIV prevention.
Unitaid is supporting manufacturers in Uganda, Kenya and South Africa to prepare for potential future production of alimatravir, a once-monthly HIV prevention pill now in Phase 3 development.
https://ow.ly/gQNK50ZIakt
Unitaid is supporting manufacturers in Uganda, Kenya and South Africa to prepare for potential future production of alimatravir, a once-monthly HIV prevention pill now in Phase 3 development.
https://ow.ly/gQNK50ZIakt
September 4, 2026 at 2:50 PM
Africa shouldn’t have to wait years for the next generation of HIV prevention.
Unitaid is supporting manufacturers in Uganda, Kenya and South Africa to prepare for potential future production of alimatravir, a once-monthly HIV prevention pill now in Phase 3 development.
https://ow.ly/gQNK50ZIakt
Unitaid is supporting manufacturers in Uganda, Kenya and South Africa to prepare for potential future production of alimatravir, a once-monthly HIV prevention pill now in Phase 3 development.
https://ow.ly/gQNK50ZIakt
Alimatravir podría convertirse en una pastilla mensual para prevenir el VIH.
Hemos pedido a la Oficina Europea de Patentes que rechace una solicitud de Merck que podría prolongar su monopolio porque consideramos que no aporta una verdadera innovación.
🔗 Más: saludporderecho.org/pedimos-a-la...
Hemos pedido a la Oficina Europea de Patentes que rechace una solicitud de Merck que podría prolongar su monopolio porque consideramos que no aporta una verdadera innovación.
🔗 Más: saludporderecho.org/pedimos-a-la...
Pedimos a la Oficina Europea de Patentes que rechace una solicitud de Merck sobre alimatravir
Desde Salud por Derecho hemos presentado, junto a otras cuatro organizaciones, observaciones ante la Oficina Europea de Patentes para pedir que no se conceda una nueva patente solicitada por Merck
saludporderecho.org
September 30, 2026 at 12:37 PM
Alimatravir podría convertirse en una pastilla mensual para prevenir el VIH.
Hemos pedido a la Oficina Europea de Patentes que rechace una solicitud de Merck que podría prolongar su monopolio porque consideramos que no aporta una verdadera innovación.
🔗 Más: saludporderecho.org/pedimos-a-la...
Hemos pedido a la Oficina Europea de Patentes que rechace una solicitud de Merck que podría prolongar su monopolio porque consideramos que no aporta una verdadera innovación.
🔗 Más: saludporderecho.org/pedimos-a-la...
JID: Alimatravir Oral Once Monthly in Adults With Low Likelihood of HIV Exposure: A Randomized, Double-Blind, Placebo-Controlled Study
by Kenneth H Mayer et al
bit.ly/4ruwaVK
by Kenneth H Mayer et al
bit.ly/4ruwaVK
September 23, 2026 at 3:58 PM
JID: Alimatravir Oral Once Monthly in Adults With Low Likelihood of HIV Exposure: A Randomized, Double-Blind, Placebo-Controlled Study
by Kenneth H Mayer et al
bit.ly/4ruwaVK
by Kenneth H Mayer et al
bit.ly/4ruwaVK
Une Prep en un seul comprimé par mois ? Dix ans après l’arrivée de la Prep en France, le Pr Jean-Michel Molina décrypte pour Remaides les enjeux du MK-8527 (alimatravir), une nouvelle stratégie qui pourrait changer la prévention du VIH : www.aides.org/actualite/la...
L’Actu vue par Remaides : « MK-8527 : une Prep en un seul comprimé par mois à l’essai. Interview du Pr Jean-Michel Molina »
Dans un entretien accordé à Remaides, le Pr Jean-Michel Molina, infectiologue, professeur de médecine et chef du service de maladies infectieuses de l’Hôpital Saint-Louis et de l’hôpital Lariboisière ...
www.aides.org
May 12, 2026 at 5:47 AM
Une Prep en un seul comprimé par mois ? Dix ans après l’arrivée de la Prep en France, le Pr Jean-Michel Molina décrypte pour Remaides les enjeux du MK-8527 (alimatravir), une nouvelle stratégie qui pourrait changer la prévention du VIH : www.aides.org/actualite/la...
En Brasil se celebra la Conferencia Internacional del VIH. En el centro del debate, el recorte de la financiación de los principales países donantes y el acceso de nuevos medicamentos. Los principales ahora mismo son 2: Lenacapavi y el Alimatravir
Allí está Luis Vallés
Allí está Luis Vallés
July 29, 2026 at 3:12 PM
En Brasil se celebra la Conferencia Internacional del VIH. En el centro del debate, el recorte de la financiación de los principales países donantes y el acceso de nuevos medicamentos. Los principales ahora mismo son 2: Lenacapavi y el Alimatravir
Allí está Luis Vallés
Allí está Luis Vallés
Innovation creates possibility. Preparation creates access.
We're investing now to help African manufacturers prepare for the potential future production of investigational once-monthly HIV prevention pill alimatravir (MK-8527), pending successful trials and regulatory approval.
We're investing now to help African manufacturers prepare for the potential future production of investigational once-monthly HIV prevention pill alimatravir (MK-8527), pending successful trials and regulatory approval.
July 24, 2026 at 3:46 PM
Innovation creates possibility. Preparation creates access.
We're investing now to help African manufacturers prepare for the potential future production of investigational once-monthly HIV prevention pill alimatravir (MK-8527), pending successful trials and regulatory approval.
We're investing now to help African manufacturers prepare for the potential future production of investigational once-monthly HIV prevention pill alimatravir (MK-8527), pending successful trials and regulatory approval.
ONCE A MONTH HIV PREVENTION PILL | Aspen will not be manufacturing the lenacapavir HIV prevention injection, and will instead focus on producing alimatravir, an experimental HIV prevention pill.
www.spotlightnsp.co.za/2026/09/21/i...
www.spotlightnsp.co.za/2026/09/21/i...
Is Aspen betting on the right HIV prevention product?
Aspen Pharmacare has announced that it will not be manufacturing the lenacapavir HIV prevention injection, and that it will instead focus on producing alimatravir, an experimental HIV prevention pill....
www.spotlightnsp.co.za
September 21, 2026 at 10:17 AM
ONCE A MONTH HIV PREVENTION PILL | Aspen will not be manufacturing the lenacapavir HIV prevention injection, and will instead focus on producing alimatravir, an experimental HIV prevention pill.
www.spotlightnsp.co.za/2026/09/21/i...
www.spotlightnsp.co.za/2026/09/21/i...
Recently LAPaL updates
New drug delivery technologies:
Multi-Arm Polymer Conjugated Immunotherapies
Plexis Long-acting Injectable Technology
New drugs:
GS-3242
Acoziborole
And we've updated:
Ulonivirine
VH-499
VH-148
Alimatravir
GS-3107
www.liverpool.ac.uk/celt-global-...
@medicinespatentpool.org
New drug delivery technologies:
Multi-Arm Polymer Conjugated Immunotherapies
Plexis Long-acting Injectable Technology
New drugs:
GS-3242
Acoziborole
And we've updated:
Ulonivirine
VH-499
VH-148
Alimatravir
GS-3107
www.liverpool.ac.uk/celt-global-...
@medicinespatentpool.org
March 31, 2026 at 11:01 AM
Recently LAPaL updates
New drug delivery technologies:
Multi-Arm Polymer Conjugated Immunotherapies
Plexis Long-acting Injectable Technology
New drugs:
GS-3242
Acoziborole
And we've updated:
Ulonivirine
VH-499
VH-148
Alimatravir
GS-3107
www.liverpool.ac.uk/celt-global-...
@medicinespatentpool.org
New drug delivery technologies:
Multi-Arm Polymer Conjugated Immunotherapies
Plexis Long-acting Injectable Technology
New drugs:
GS-3242
Acoziborole
And we've updated:
Ulonivirine
VH-499
VH-148
Alimatravir
GS-3107
www.liverpool.ac.uk/celt-global-...
@medicinespatentpool.org
Our new issue of #PxWire cover's Merck/MSD’s decision to license #alimatravir to 7 generic manufacturers before efficacy results, setting a benchmark for access.
But gaps remain, including the exclusion of Brazil & other countries from the license.
Read more: avac.org/resource/rep...
#PrEP #HIV
But gaps remain, including the exclusion of Brazil & other countries from the license.
Read more: avac.org/resource/rep...
#PrEP #HIV
August 27, 2026 at 2:49 PM
Our new issue of #PxWire cover's Merck/MSD’s decision to license #alimatravir to 7 generic manufacturers before efficacy results, setting a benchmark for access.
But gaps remain, including the exclusion of Brazil & other countries from the license.
Read more: avac.org/resource/rep...
#PrEP #HIV
But gaps remain, including the exclusion of Brazil & other countries from the license.
Read more: avac.org/resource/rep...
#PrEP #HIV
2️⃣ #HIV- Aktivist*innen kritisieren, dass viele Länder mit mittleren Einkommen von der freiwilligen Generika-Lizenz für die #Alimatravir- #PrEP ausgeschlossen wären (darunter viele Länder in Lateinamerika, z.B. Brasilien).
/3
/3
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir If Alimatravir is Approved, Merck’s Unethical Exclusion of Middle Inc...
healthgap.org
July 24, 2026 at 3:38 PM
2️⃣ #HIV- Aktivist*innen kritisieren, dass viele Länder mit mittleren Einkommen von der freiwilligen Generika-Lizenz für die #Alimatravir- #PrEP ausgeschlossen wären (darunter viele Länder in Lateinamerika, z.B. Brasilien).
/3
/3
#HIV- Aktivist*innen kritisieren das Pharmaunternehmen Merck / MSD: Die Ankündigung freiwilliger Generika-Lizenzen des - noch nicht zugelassenen - #PrEP- Wirkstoffs #Alimatravir ( #MK8527) sei unethisch, weil viele Länder z.B. in Lateinamerika - darunter Brasilien - ausgeschlossen seien.
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir
Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir If Alimatravir is Approved, Merck’s Unethical Exclusion of Middle Inc...
healthgap.org
July 24, 2026 at 2:52 PM
#HIV- Aktivist*innen kritisieren das Pharmaunternehmen Merck / MSD: Die Ankündigung freiwilliger Generika-Lizenzen des - noch nicht zugelassenen - #PrEP- Wirkstoffs #Alimatravir ( #MK8527) sei unethisch, weil viele Länder z.B. in Lateinamerika - darunter Brasilien - ausgeschlossen seien.
We're at the #AIDS2026 #HIVprevention precon & just heard from Merck's Rebeca Plank, who shared updates on #MK-8527 #alimatravir, the monthly oral #PrEP candidate. Here are a few highlights. Visit AVAC for all things MK-8527, www.prepwatch.org/products/mk-...
#PrEP #HIVPrevention
#PrEP #HIVPrevention
July 26, 2026 at 1:18 PM
We're at the #AIDS2026 #HIVprevention precon & just heard from Merck's Rebeca Plank, who shared updates on #MK-8527 #alimatravir, the monthly oral #PrEP candidate. Here are a few highlights. Visit AVAC for all things MK-8527, www.prepwatch.org/products/mk-...
#PrEP #HIVPrevention
#PrEP #HIVPrevention
2️⃣ Noch ist kein Zulassungsantrag für die #Alimatravir- #PrEP gestellt, aber Merck/MSD konnte die Ankündigung, Generika-Lizenzen für 129 Länder mit geringen bis mittleren Einkommen zu vergeben, gut in die Öffentlichkeit bringen. Gerade Länder mit hohen #HIV- Infektionszahlen gehören aber nicht dazu.
July 29, 2026 at 3:43 PM
2️⃣ Noch ist kein Zulassungsantrag für die #Alimatravir- #PrEP gestellt, aber Merck/MSD konnte die Ankündigung, Generika-Lizenzen für 129 Länder mit geringen bis mittleren Einkommen zu vergeben, gut in die Öffentlichkeit bringen. Gerade Länder mit hohen #HIV- Infektionszahlen gehören aber nicht dazu.
New in @thelancetinfdis.bsky.social.
"AVAC said it wanted to see Merck pledge to reach at least 2M people with #alimatravir w/in the 1st yr of product launch & 5M w/in the first 2 years & guarantee it will be available in LMICs w/in 3 months of first approval."
www.thelancet.com/journals/lan...
"AVAC said it wanted to see Merck pledge to reach at least 2M people with #alimatravir w/in the 1st yr of product launch & 5M w/in the first 2 years & guarantee it will be available in LMICs w/in 3 months of first approval."
www.thelancet.com/journals/lan...
Merck's alimatravir licensing deal receives mixed response
In July 2026, Merck announced licensing agreements with seven manufacturers for generic
production of its HIV drug alimatravir, though access and equity concerns remain.
Ed Holt reports.
www.thelancet.com
August 13, 2026 at 3:40 PM
New in @thelancetinfdis.bsky.social.
"AVAC said it wanted to see Merck pledge to reach at least 2M people with #alimatravir w/in the 1st yr of product launch & 5M w/in the first 2 years & guarantee it will be available in LMICs w/in 3 months of first approval."
www.thelancet.com/journals/lan...
"AVAC said it wanted to see Merck pledge to reach at least 2M people with #alimatravir w/in the 1st yr of product launch & 5M w/in the first 2 years & guarantee it will be available in LMICs w/in 3 months of first approval."
www.thelancet.com/journals/lan...
🧵1️⃣ Der Wirkstoff #Alimatravir zum Schutz vor #HIV (auch bekannt als MK-8527) könnte für 3 Dollar pro Person und Jahr produziert werden, so eine Studie, über die @aidsmap.bsky.social berichtet. Noch ist allerdings die Phase-3-Studie nicht abgeschlossen, Ergebnisse werden Ende 2027 erwartet. /2
Monthly PrEP pill could be made for US$3 a year, but Latin America is shut out of generic licensing
Merck's investigational once-monthly PrEP pill could be manufactured and sold profitably for around $3 per person per year, making it the cheapest HIV prevention drug ever brought to market, the 26th ...
www.aidsmap.com
July 29, 2026 at 3:41 PM
🧵1️⃣ Der Wirkstoff #Alimatravir zum Schutz vor #HIV (auch bekannt als MK-8527) könnte für 3 Dollar pro Person und Jahr produziert werden, so eine Studie, über die @aidsmap.bsky.social berichtet. Noch ist allerdings die Phase-3-Studie nicht abgeschlossen, Ergebnisse werden Ende 2027 erwartet. /2